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Abstract
Background and Purpose It is important to identify patients with head and neck squamous cell carcinoma
(SCC) who fail to respond to chemoradiotherapy so that they can undergo post-treatment salvage surgery
while the disease is still operable. This study aimed to determine the diagnostic performance of dynamic
contrast enhanced (DCE)-MRI using a pharmacokinetic model for pre-treatment predictive imaging, as well
as post-treatment diagnosis, of residual SCC at primary and nodal sites in the head and neck. Material and
Methods Forty-nine patients with 83 SCC sites (primary and/or nodal) underwent pre-treatment DCEMRI,
and 43 patients underwent post-treatment DCE-MRI, of which 33 SCC sites had a residual mass amenable to
analysis. Pre-treatment, post-treatment and %change in the mean Ktrans, kep, ve and AUGC were obtained
from SCC sites. Logistic regression was used to correlate DCE parameters at each SCC site with treatment
response at the same site, based on clinical outcome at that site at a minimum of two years. Results None of
the pre-treatment DCE-MRI parameters showed significant correlations with SCC site failure (SF) (29/83
sites) or site control (SC) (54/83 sites). Post-treatment residual masses with SF (14/33) had significantly
higher kep (p = 0.05), higher AUGC (p = 0.02), and lower % reduction in AUGC (p = 0.02), than residual
masses with SC (19/33), with the% change in AUGC remaining significant on multivariate analysis.
Conclusion Pre-treatment DCE-MRI did not predict which SCC sites would fail treatment, but post-
treatment DCE-MRI showed potential for identifying residual masses that had failed treatment.
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Abstract
Background and Purpose
It is important to identify patients with head and neck squamous cell carcinoma (SCC) who
fail to respond to chemoradiotherapy so that they can undergo post-treatment salvage
surgery while the disease is still operable. This study aimed to determine the diagnostic per-
formance of dynamic contrast enhanced (DCE)-MRI using a pharmacokinetic model for
pre-treatment predictive imaging, as well as post-treatment diagnosis, of residual SCC at
primary and nodal sites in the head and neck.
Material and Methods
Forty-nine patients with 83 SCC sites (primary and/or nodal) underwent pre-treatment DCE-
MRI, and 43 patients underwent post-treatment DCE-MRI, of which 33 SCC sites had a
residual mass amenable to analysis. Pre-treatment, post-treatment and % change in the
mean Ktrans, kep, ve and AUGC were obtained from SCC sites. Logistic regression was used
to correlate DCE parameters at each SCC site with treatment response at the same site,
based on clinical outcome at that site at a minimum of two years.
Results
None of the pre-treatment DCE-MRI parameters showed significant correlations with SCC
site failure (SF) (29/83 sites) or site control (SC) (54/83 sites). Post-treatment residual mas-
ses with SF (14/33) had significantly higher kep (p = 0.05), higher AUGC (p = 0.02), and
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lower % reduction in AUGC (p = 0.02), than residual masses with SC (19/33), with the %
change in AUGC remaining significant on multivariate analysis.
Conclusion
Pre-treatment DCE-MRI did not predict which SCC sites would fail treatment, but post-treat-
ment DCE-MRI showed potential for identifying residual masses that had failed treatment.
Introduction
While neovascularization is necessary for the growth and spread of head and neck squamous
cell carcinomas (SCC), it also influences the response to chemoradiotherapy (CRT) and radio-
therapy (RT). Dynamic contrast enhanced MRI (DCE-MRI) provides a non-invasive in-vivo
method to evaluate the perfusion and permeability of these abnormal blood vessels and so pro-
vides an indirect method of assessing the hypoxic nature of a tumor [1], which is an important
factor in treatment resistance. Pre-treatment DCE-MRI, therefore, may be able to predict
which primary and nodal SCC sites in the head and neck will fail treatment. This information
would be valuable not only for the radiation oncologist, to target specific SCC sites for a radio-
therapy boost, but also for the radiologist to identify SCC sites with a higher likelihood of resid-
ual cancer, so that these sites can undergo post-treatment biopsy or close follow-up by
imaging. In addition post-treatment DCE-MRI of a residual mass in the primary or nodal bed
may improve the diagnostic ability of MRI to distinguish a residual mass that still contains can-
cer from one that is benign, so that primary or nodal resection can be performed before the
cancer has chance to regrow and render the patient inoperable.
DCE-MRI shows promise for predicting and monitoring treatment response for a range of
cancers outside of the head and neck [2, 3]. In regard to head and neck SCC, several DCE stud-
ies have shown favorable outcomes for SCCs with high vascularity on the pre-treatment
DCE-MRI [4–13], but DCE methods, parameters and thresholds are variable, and few studies
correlate DCE parameters at a specific site with treatment response at the same site. There are
even fewer post-treatment DCE studies. Post-treatment DCE-MRI has shown a favorable
response in a residual mass when there is later or less enhancement [11, 14–15], but using
pharmacokinetic models an increase in vascular markers on the post-treatment DCE-MRI has
been associated with a favorable response [16].
The aim of this study was to evaluate the ability of DCE-MRI to identify SCC sites in the
head and neck that are at risk of treatment failure using a pharmacokinetic model. We report a
prospective study in which DCE-MRI of the head and neck was performed pre-treatment for
prediction and post-treatment for diagnosis. The DCE-MRI data was obtained from individual
SCC sites in the head and neck and compared with treatment response at the same site, based
on clinical outcome at that site at a minimum of two years.
Methods
Patients
This prospective study was approved by The Joint Chinese University of Hong Kong New Ter-
ritories East Cluster Clinical Research Ethics Committee(The Joint CUHK-NTEC CREC) and
conducted following informed written consent. Patients with head and neck SCC treated with
curative intent with RT or CRT were included in the study. The pre-treatment diagnosis of
DCE-MRI for Pre-Treatment Prediction and Post-Treatment Assessment of Treatment Response in HNSCC
PLOSONE | DOI:10.1371/journal.pone.0144770 December 10, 2015 2 / 15
Abbreviations: SCC, Squamous cell carcinoma;
DCE-MRI, Dynamic contrast enhanced MRI; CRT,
Chemoradiotherapy; RT, Radiotherapy; SC, Site
control; SF, Site failure; Ktrans, Volume transfer
constant between the blood plasma and extracellular
extravascular space; kep, Rate constant between the
extracellular extravascular space and blood plasma;
ve, Volume of the extracellular extravascular space
per unit volume of tissue; AUGC, Area under
Gadolinium concentration-time curve.
SCC at the primary site was made on histology and at nodal sites on MRI imaging criteria {a
minimum axial diameter of10 mm with the exception of jugulodigastric (11mm) and ret-
ropharyngeal nodes (5mm), or any sized node with necrosis or extra nodal neoplastic
spread}. Radiotherapy was delivered to the primary tumor, metastatic regional lymph nodes,
and sites at risk of microscopic spread to 54 Gy/ 30 fractions/ 6 weeks. A concomitant boost
(18 Gy/ 12 fractions) was given to the gross tumor as a second daily dose in the last 12 treat-
ment days. Concurrent chemotherapy consisted of intravenous cisplatin 40 mg/m2 given
weekly on days 1, 8, 15, and 22 of RT.
DCE-MRI data acquisition
MRI was performed on a 3T MRI scanner (Achieva, Philips Healthcare, Best, The Netherlands)
using a 16 channel sensitivity encoding head and neck coil. Before performing DCE-MRI, rou-
tine protocol T1 and T2 weighted images were acquired. The DCE-MRI sequence was obtained
using a short 3D T1-weighted spoiled gradient echo sequence in the axial plane covering the
entire tumor (TR = 4.0 ms, TE = 1.0ms, flip angle = 15°, matrix = 128 × 128, number of
slices = 25, slice thickness = 4 mm, number of signal averages = 1, sensitivity encoding fac-
tor = 3, temporal resolution = 2.59s/dynamic, number of dynamics = 185, and scanning
time = 460s). Before dynamic acquisition, a flip angle of 2° was used with other parameters
identical to dynamic acquisition to derive the pre-contrast T1 map. Contrast injection was
commenced 6 seconds after the start of the dynamic MRI acquisitions, given in the form of a
bolus injection of gadopenetate dimeglumine (Dotarem, Guerbet, France) at a concentration of
0.1 mmol/kg of body weight. A power injection pump (Medrad, Pittsburgh, PA) was used set
at an injection rate of 3.0 ml/s through a 21-gauge intravenous catheter in an antecubital vein.
The injection was followed by a 20-ml saline flush at the same injection rate. Following the
DCE-MRI scan, post-contrast enhanced anatomical T1-weighted images were acquired as part
of the routine clinical examination. The post-treatment scan was performed using the same
DCE-MRI protocol 6 weeks +/- 3 weeks following the end of treatment.
DCE-MRI data processing and analysis
DCE-MRI data were exported in a Philips PAR/REC format and then processed using the Phil-
ips PRIDE research tool v5.2 (Philips Healthcare, Best, The Netherlands) with the DCE-MRI
images non-rigidly registered to the first dynamic image to compensate for possible patient
movement. Voxels for arterial input function extraction were manually selected from the
carotid arteries. Time intensity curves for arteries and tumors were converted into time-con-
centration-curves using the dual-flip-angle (2° and 15°) derived pre-contrast T1 map [17], a
contrast agent r1 relaxivity value of 4.5s-1mM-1 and an assumed hematocrit value of 0.42. The
DCE-MRI pharmacokinetic parameter maps were generated using the extracted arterial input
function based on the Tofts model [18, 19].
The entire volume of each pre-treatment SCC site (primary site or metastatic nodal site)
and any residual masses at these SCC sites, were outlined on the T1W dynamic images by a
specialist head and neck radiologist using the T2-weighted and T1-weighted post-contrast
axial images for guidance. The voxel-wise Ktrans min-1, (the volume transfer constant between
the blood plasma and extracellular extravascular space), kep min
-1, (rate constant between the
extracellular extravascular space and blood plasma), ve (volume of the extracellular extravascu-
lar space per unit volume of tissue) were calculated using the non-linear least-square fitting
algorithm using Philips PRIDE software. The goodness-of-fit (R2) was set as 0.7 for fitting. The
area under the gadolinium concentration-time curve (AUGC) was also calculated for the
whole time-concentration-curve.
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The volume of each pre-treatment SCC site and the volume of any residual post-treatment
mass at that site were measured.
Assessment of treatment response
DCE-MRI parameters of each SCC site (primary or nodal) were correlated with subsequent
site control (SC) or site failure (SF) at the same site. SF was determined by histological confir-
mation of SCC; radiological evaluation (increase in the size of a residual mass in the tumor bed
or development of a new mass in the tumor bed on follow-up imaging); clinical evaluation
(visualization of a definite tumor at the primary site, or increase in size of a primary or nodal
mass on follow-up). SC was defined by absence of SCC at surgical resection or absence of SF on
follow-up for least two years after the end of treatment.
Statistical Analysis
The mean Ktrans, kep, ve, AUGC and volume were evaluated. Univariate logistic regression anal-
yses of each parameter pre-treatment, post-treatment, and percentage (%) change in each of
these parameters from pre-treatment to post-treatment, were carried out to determine if there
was a correlation between the DCE-MRI and volume parameters and treatment outcome at the
same SCC site. Clinical factors were also assessed {age, sex, site (primary vs. node), T stage (T1/
2 vs. T3/4), N stage (N0/N1 vs.N2/N3) and treatment regimes (RT, CRT and Induction CRT)}.
Odds ratios and their corresponding 95% CIs were calculated in univariate analysis, parameters
with p-values of less than 0.05 were included in a multivariate analysis with stepwise method.
Adjusted odd ratios and corresponding 95% CIs were performed with confounding factors of
site, T stage, N stage, tumor volume and treatment, in the model. Receiver-operating character-
istics analyses with the area under the curve were employed to identify the optimal thresholds
of significant parameters by giving equal weighting to sensitivity and specificity. The sensitiv-
ity, specificity, accuracy, positive predictive value and negative predictive value of this thresh-
old were calculated, and the significance was re-evaluated with the Fisher’s exact test. In
addition the paired t-test was used to compare mean DCE-MRI parameters and volumes pre-
treatment and post-treatment at all sites with a residual post-treatment mass. All statistical
tests were two sided, and p-values of less than 0.05 were considered to indicate a statistically
significant difference. The software SAS version 9.3 (SAS Institute Inc, Cory, NC, USA) was
used for statistical analysis.
Results
Patients
Pre-treatment DCE-MRI was performed on 85 patients with head and neck SCC. Of these 85
patients, 36 were excluded from the study; in 26 patients the planned treatment was changed to
surgery, 5 patients subsequently did not undergo or complete a course of CRT/RT, 3 patients
died before SF or SC could be confirmed, in one patient the AIF could not be obtained and in
another the images were degraded. The study therefore comprised 49 patients (42 males and 7
females, median age 60 years, age range 41–93 years) presenting with primary SCCs of the oro-
pharynx = 19; larynx = 14; hypopharynx = 12; and oral cavity = 4 (T stages were T1 = 1;
T2 = 18; T3 = 13; T4 = 17). Nodal metastases were present in 35/49 patients (N0 = 14, N1 = 3,
N2 = 31, N3 = 1). Patients underwent treatment with intensity modulated radiotherapy
(IMRT) {with (1) or without (5) induction chemotherapy}, or IMRT concurrent with cisplatin
or cetuximab {with (10) or without (33) induction chemotherapy}. Following treatment, a
post-treatment DCE-MRI could not be obtained for analysis in 6/49 patients; an MRI was not
DCE-MRI for Pre-Treatment Prediction and Post-Treatment Assessment of Treatment Response in HNSCC
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performed (n = 1), renal impairment prevented the administration of contrast (n = 2), or the
MRI was delayed (n = 3). The remaining 43 patients underwent a post-treatment DCE-MRI
(mean = 43.3 days, median = 44.0 days, range = 23–62 days).
Pre-treatment DCE data in the 49 patients were obtained from primary and/or nodal sites
{primary site = 19; nodal site = 5; two nodal sites = 1; primary site + one nodal site = 18; pri-
mary site +> one nodal site = 6 (2 nodal sites = 4, 3 nodal sites = 1, 4 nodal sites = 1)}. SF
occurred in 21/49 patients (primary site = 9; one nodal site = 5; primary site + one nodal
site = 6; primary site + two nodal sites = 1). Of the 31 patients with a residual mass (primary
site = 17; nodal site = 12; primary site + one nodal site = 2), SF occurred in 13/31 patients (pri-
mary site = 6; nodal site = 6; primary site + one nodal site = 1).
SCC Sites
Pre-treatment 83 SCC sites underwent DCE, 43 primary sites and 40 nodal sites (minimum
axial diameter of metastatic nodes ranged from 11mm-35.6mm; mean 16.9mm). SC occurred
in 54/83 sites (primary site = 27; nodal site = 27) at a mean of 42.6 months, median 39.8; range
24–68.0 months of follow-up time for patients with conservative management without salvage
surgery. SF occurred in 29/83 sites (primary site = 16; nodal site = 13) at a mean of 7.2 months;
median 6.1 months, range 1.3–34.5 months.
Post-treatment 71/83 sites underwent DCE-MRI, of these 38 were excluded from analysis
because there was no residual mass or the residual mass was too small or necrotic for analysis.
Therefore, 33 sites with a residual mass underwent both pre-treatment and post-treatment
DCE-MRI analysis, of which 19 had SC (primary site = 12; nodal site = 7) at a mean 43.1
months, median 41.2 months, range 24.0–68.0 months, and 14 had SF (primary site = 7; nodal
site = 7) at a mean 6.0 months, median 6.2 months, range 1.6–14.26 months.
DCE-MRI, Volume and Clinical parameters
1. Pre-treatment parameters at SCC sites correlated with SF or SC. The mean Ktrans, kep,
ve, AUGC, volume and clinical factors for all 83 SCC sites in the head and neck pre-treatment
are shown in Table 1. The pre-treatment Ktrans, kep, ve, and AUGC were higher and volume
lower in SCC sites with SC compared to SF, but the results were not statistically significant
(Table 1). Clinical parameters were not significantly different between sites with SC and SF
(Table 1). When the model was adjusted for confounding factors none of the DCE parameters
were significant. When the primary and nodal sites were analyzed separately the DCE parame-
ters and volumes of these sites showed no correlation with treatment outcome either (Table 2).
2. Comparison between Pre-treatment and Post-treatment parameters at SCC sites with
a residual mass. Comparing mean DCE parameters and volumes at SCC sites pre and post-
treatment, there was a significant decrease in kep (0.67 ± 0.28 vs. 0.42 ± 0.24, p< 0.001) and
volume (5.25 ± 6.31 vs. 1.10 ± 1.83, p< 0.001); a significant increase in ve (0.57 ± 0.19 vs.
0.79 ± 0.23, p =< 0.001); no significant change in Ktrans (0.37 ± 0.16 vs. 0.30 ± 0.15, p = 0.092)
or AUGC (2.42 ± 0.71 vs. 2.49 ± 1.05, p = 0.732) using the Paired-t-test.
3. Comparison of Post-treatment residual masses with SC and SF. The mean Ktrans, kep,
ve, AUGC and volume and respective % change compared to pre-treatment at 33 sites with a
residual mass with SC and SF are shown in Table 3, together with the clinical parameters. SC
residual masses showed significantly lower kep and AUGC compared with SF residual masses
(p = 0.049 and p = 0.023 respectively) (Fig 1A–1F and Fig 2A–2F). In regard to % change when
compared to pre-treatment SC residual masses showed a decrease in the AUGC while the SF
residual masses showed an increase in AUGC (Fig 3), the % change in AUGC being signifi-
cantly different between these two groups (p = 0.015). All other DCE parameters, volumes and
DCE-MRI for Pre-Treatment Prediction and Post-Treatment Assessment of Treatment Response in HNSCC
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clinical parameters showed no significant differences between residual masses with SC and SF.
Multivariate analysis of significant post-treatment parameters (kep, AUGC and the % change
in AUGC) found the % change in AUGC remained significant (p = 0.015; OR 1.021; 95% CI
for OR 1.004–1.039) and when the model was adjusted for the size and confounding factors,
the % change in AUGC was still significant (p = 0.021; Adjusted OR 1.024; 95% CI for adjusted
OR 1.003–1.044). Receiver-operating characteristics analysis (Fig 4) produced an area under
the curve of 0.77 (95% CI = 0.594–0.940) and when using a> 19.78% increase in AUGC to pre-
dict a SF residual mass produced a diagnostic performance which is shown in Table 4. When
the primary and nodal residual mass sites were analyzed separately the DCE parameters and
volumes of these sites showed no correlation with treatment outcome (Table 5).
Discussion
In this study none of the pre-treatment DCE-MRI parameters obtained from SCC sites in the
head and neck were predictors of treatment response at the same SCC site based on clinical
Table 1. Pre-treatment mean DCE, volumes and clinical parameters in 83 SCC sites (primary plus nodal) correlated with SF or SC at the same site,
based on a minimum of 2 year clinical follow-up.
Parameter Pre-treatment
Parameters for all
SCC sites
Pre-treatment SCC
sites with Site
Failure (SF)
Pre-treatment SCC
sites with Site
Control (SC)
p-value comparing SCC
sites with SF & SC using
Logistic Regression
Odds
Ratio
(OR)
95% CI
for OR
n = 83 n = 29 n = 54
Ktrans (min-1) 0.37 ± 0.19 0.33 ± 0.14 0.39 ± 0.21 0.212 0.195 0.015–
2.544
kep (min
-1) 0.67 ± 0.30 0.64 ± 0.25 0.68 ± 0.32 0.575 0.642 0.136–
3.024
ve 0.56 ± 0.21 0.53 ± 0.17 0.58 ± 0.23 0.319 0.327 0.036–
2.941
AUGC (mMs) 2.38 ± 0.79 2.15 ± 0.70 2.50 ± 0.81 0.063 0.555 0.299–
1.032
Volume (cm3) 4.35 ± 5.63 5.19 ± 7.11 3.90 ± 4.65 0.327 1.040 0.961–
1.126
Age 61.3 ± 8.8 62.4 ± 8.7 60.6 ± 8.9 0.385 1.023 0.972–
1.078
Sex Male
(compared to
female)
74 27 47 0.404 2.011 0.390–
10.378
T Stage T3/4
(compared to T1/2)
57 20 37 0.967 1.021 0.385–
2.704
N Stage N2/3
(compared to N0/
N1)
68 24 44 0.156 2.404 0.715–
8.076
Site Primary site
(compared to nodal
site)
43 16 27 0.653 1.231 0.498–
3.044
Treatment 0.174 0.546 0.229–
1.305
1. RT 6 2 4
2. CRT without
induction CRT
56 23 33
3. Induction chemo
CRT
21 4 17
± Standard deviation.
doi:10.1371/journal.pone.0144770.t001
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outcome at a minimum of two years. Although SCC sites with control showed higher pre-treat-
ment perfusivity and permeability (Ktrans, kep and AUGC) and higher extracellular extravascu-
lar space (ve) compared to SCC sites with failure, none of these parameters proved to be
significantly different between these two groups. On the other hand, treatment led to signifi-
cantly lower tumor perfusivity (kep) and higher extracellular extravascular volume fraction
(ve), and after treatment the perfusivity of a residual mass with SC was significantly lower than
that of a residual mass with SF, based on the kep and AUGC results. The % change in the
AUGC, from pre-treatment to post-treatment was also a predictor of response, SCCs with less
reduction in the AUGC were more likely to have SF. Interestingly the mean % change in the SF
group showed an AUGC increase, whereas for the SC group there was an AUGC decrease.
This suggests an increase in the AUGC after treatment could be a marker for residual head and
neck SCC. However, the optimum threshold for the % AUGC change (>19.78% increase for
SF) produced a relatively low diagnostic performance for DCE-MRI, especially when compared
to the current imaging standard of 18FDG- PET/ CT at 3 months [20]. Of note the negative pre-
dictive value, which is valuable for excluding disease, was only 79% for DCE-MRI, compared
to around 95% for 18FDG-PET/ CT [20].
Previous pre-treatment head and neck SCC DCE-MRI studies using pharmacokinetic mod-
els have found high mean Ktrans [5, 7, 9,10], low Ktrans skewness [6] or high ve [9] to be predic-
tors of a favorable outcome, based on prolonged disease free survival [5], progression free and
overall survival in stage IV disease [6], non-response in nodes based on locoregional recurrence
or death [7], neck control rates [9], and recurrence (primary, nodal or distant sites) [10]. How-
ever, the focus of our research was to evaluate the ability of DCE-MRI to predict treatment
response at specific primary or nodal SCC sites in the head and neck, so that this information
Table 2. Pre-treatment mean DCE parameters in 43 primary sites and 40 nodal sites correlated with SF or SC at the same SCC site, based on a min-
imum of 2 year clinical follow-up.
Parameter Pre-treatment for
all SCC sites
Pre-treatment SCC
sites with Site Failure
(SF)
Pre-treatment SCC
sites with Site Control
(SC)
p-value comparing SCC sites
with SF & SC using Logistic
Regression
Odds
Ratio
(OR)
95% CI
for OR
Primary
Tumor Sites
n = 43 n = 16 n = 27
Ktrans (min-1) 0.38 ± 0.18 0.37 ± 0.16 0.39 ± 0.19 0.731 0.539 0.016–
18.243
kep (min
-1) 0.69 ± 0.32 0.70 ± 0.30 0.69 ± 0.33 0.916 1.112 0.154–
8.015
ve 0.57 ± 0.23 0.54 ± 0.20 0.59 ± 0.25 0.498 0.385 0.024–
6.062
AUGC (mMs) 2.44 ± 0.75 2.18 ± 0.60 2.59 ± 0.79 0.086 0.438 0.171–
1.123
Nodal Tumor
Sites
n = 40 n = 13 n = 27
Ktrans (min-1) 0.35 ± 0.20 0.28 ± 0.09 0.38 ± 0.24 0.157 0.047 0.001–
3.250
kep (min
-1) 0.64 ± 0.29 0.27 ± 0.16 0.67 ± 0.33 0.301 0.251 0.018–
3.445
ve 0.54 ± 0.19 0.51 ± 0.12 0.56 ± 0.22 0.416 0.220 0.006–
8.464
AUGC (mMs) 2.31 ± 0.84 2.12 ± 0.82 2.40 ± 0.84 0.324 0.655 0.282–
1.520
± Standard deviation.
doi:10.1371/journal.pone.0144770.t002
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could be used to identify those sites at risk of failure after treatment. This would enable patients
to undergo a post-treatment biopsy targeted to a specific SCC site or undergo 18FDG-PET/CT
at 3 months. Those patients without a post-treatment diagnosis of residual cancer, who never-
theless had an abnormal DCE examination, could be selected for closer MRI follow-up with
the aim of identifying residual cancers before they have chance to regrow and present later on
as tumor recurrence. To the best of our knowledge only three pre-treatment studies have
addressed this specific area using pharmacokinetic models [4, 8, 16]. Two of these studies
Table 3. Post treatment residual mass in 33 SCC sites (primary plus nodal): mean DCE and volumes (and% change when compared to pre-treat-
ment), and clinical parameters for SC residual masses and SF residual masses, based on aminimum of 2 year clinical follow-up.
Parameter Post-treatment Residual
mass with Site Failure (SF)
Post-treatment Residual
mass with Site Control (SC)
p-value comparing residual
masses with SC & SF using
Logistic regression
Odds
Ratio
(OR)
95% CI
for OR
n = 14 n = 19
Ktrans (min-1) 0.35 ± 0.14 0.26 ± 0.16 0.098 69.879 0.457–
999.
% Change Ktrans 16.09 ± 71.80 -20.32 ± 50.93 0.129 1.012 0.997–
1.027
kep (min
-1) 0.52 ± 0.23 0.35 ± 0.23 0.049 29.692 1.017–
866.979
% Change kep -15.90 ± 52.43 -34.27 ± 53.75 0.329 1.007 0.993–
1.020
ve 0.75 ± 0.18 0.83 ± 0.26 0.353 0.232 0.011–
5.072
% Change ve 53.10 ± 48.48 55.46 ± 90.80 0.928 1.000 0.990–
1.009
AUGC (mMs) 3.00 ± 1.06 2.11 ± 0.89 0.023 2.639 1.146–
6.073
% Change AUGC 42.64 ± 64.83 -12.63 ± 39.86 0.015 1.021 1.004–
1.039
Volume (cm3) 1.47 ± 2.71 0.83 ± 0.66 0.399 1.264 0.733–
2.180
% Change in volume -0.68 ± 0.22 -0.74 ± 0.16 0.308 7.502 0.156–
360.156
Age 63.8 ±10.7 61.8 ±11.2 0.585 1.018 0.954–
1.087
Sex Male (compared
to female)
13 (92.9) 14 (73.7) 0.186 4.642 0.477–
45.197
T Stage T3/4
(compared to T1/2)
9 (64.3) 15 (79.0) 0.354 0.480 0.102–
2.268
N Stage N2/3
(compared to N0/N1)
11 (78.6) 14 (73.7) 0.164 3.500 0.600–
20.414
Site Primary site
(compared to nodal
site)
7 (50.0) 7 (36.8) 0.451 1.714 0.422–
6.968
Treatment 0.115 0.179 0.021–
1.515
1. RT 1 1
2. CRT without
induction CRT
13 13
3. Induction chemo
CRT
0 5
± Standard deviation.
doi:10.1371/journal.pone.0144770.t003
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found a correlation between high pre-treatment Ktrans and SC, the first in 33 metastatic nodal
SCC sites based on follow-up at 6 months [4] and the second in 58 primary SCC sites with fol-
low-up period to death or a minimum of 12 months [8]. The third study based on histology
from the surgical resection after CRT found no correlation between DCE-MRI parameters and
treatment response [16] which is similar to our results. Therefore, at present there is insuffi-
cient data to determine whether pre-treatment DCE-MRI using pharmacokinetic modelling
can be used to predict which SCC sites are at risk of treatment failure.
Post-treatment examination of residual abnormalities is an even greater challenge for
DCE-MRI than pre-treatment examination of the tumor. To the best of our knowledge only
one post-treatment SCC study used a pharmacokinetic model to evaluate similar DCE parame-
ters to those in our study [16]. That study performed DCE-MRI two weeks after CRT and cor-
related the results with histology from the surgical specimen of 35 primary oral SCCs. A
significant increase in ve, AUGC, and K
trans, together with a significantly higher post-treatment
ve and AUGC were found in responders compared to non responders. Our results also showed
an increase in the extravascular extracellular space (ve) in responders, (not significant), but our
other DCE parameters had decreased after treatment. However, DCE-MRI data from time
Fig 1. MRI, AUGC and kep maps in the axial plane from a 70 year old male with oropharyngeal carcinoma and SC 46.7 months after
chemoradiotherapy. (a) Pre-treatment T1-weighted post contrast image of the SCC, (b) Pre-treatment AUGCmap (mean AUGC = 2.36), (c) Pre-treatment
kep map (mean kep = 1.62); (d) Post-treatment T1-weighted post contrast image of the SC residual mass, (e) Post-treatment AUGCmap (mean
AUGC = 0.96), (f) Post-treatment kep map (mean kep = 0.09).
doi:10.1371/journal.pone.0144770.g001
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intensity curves in head and neck SCC [11, 15], and from pharmacokinetic models in breast
and colorectal cancers, using kep and K
trans [21–25], are broadly in line with those from our
study. We have observed a greater % reduction in the AUGC, and a lower AUGC and kep in SC
residual masses compared to SF residual masses. The AUGC is considered to be more robust
and simpler to quantify than those DCE-MRI parameters obtained from pharmacokinetic
models, because it does not require an arterial input function and is less influenced by the com-
plicated computation procedure in pharmacokinetic model fitting. The AUGC reflects the
accumulation and/or depletion of contrast media within the cancer regardless of curve shape,
although it has no direct correlation with the contrast circulation pathway, nor is it able to
reflect any specific physiological processes such as perfusion or permeability. The AUGC is still
subject to contrast injection protocol and dynamic imaging parameter setting and as such,
cross-centre comparison of AUGCmay become difficult. However, the % change in AUGC
may be comparable across centers provided the DCE-MRI acquisition protocol is kept constant
for the pre-treatment and post-treatment scans.
In this prospective study we used long-term clinical outcome with a minimum of 2 year fol-
low up at each site, which is a superior to assessment of change in tumor size post-treatment.
Nethertheless, there are several limitations to the study. We speculate that parameter
Fig 2. MRI, AUGC and kep maps in the axial plane from an 85 year old male with oral cavity carcinomawith SF 3.6 months after chemoradiotherapy.
(a) Pre-treatment T1-weighted post contrast image of the SCC, (b) Pre-treatment AUGCmap (mean AUGC = 3.07), (c) Pre-treatment kep map (mean kep =
0.88); (d) Post-treatment T1-weighted post contrast image of the residual mass with SF, (e) Post-treatment AUGCmap AUGC (mean AUGC = 3.72), (f) Post-
treatment kep map (mean kep = 0.63).
doi:10.1371/journal.pone.0144770.g002
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quantification of pharmacokinetic modeling requires further development and could be one of
the reasons for the insignificant correlation from the pre-treatment study. Parameter quantifi-
cation of pharmacokinetic modeling is complicated and subject to many factors, including but
not limited to tissue properties, contrast agent registration, DCE-MRI imaging protocol, as
well as the fitting method [26]. One main concern is the accurate estimation of the arterial
input function which is a problem encountered by all researchers in this field. Many methods
have been proposed for obtaining the arterial input function, including the individual based
arterial input function and population based arterial input function, but currently all methods
have drawbacks [26]. In addition, several of our results obtained ve values that were unexpect-
edly high, a problem also identified by other researchers including those studying head and
neck SCC [4].
Head and neck SCC are heterogeneous tumors and so this study collected each DCE param-
eter from the entire tumor volume, rather than from small regions of interest or the largest
cross sectional area. However, only the mean DCE parameter was measured and other mea-
sures for probing tumor heterogeneity were not assessed, such as assessment of the distribution
of DCE parameters using skewness [6].
Seven patients in this study had data collection from more than one nodal site in the head
and neck, one of whom had two sites of SF that were included in analysis of the pre-treatment
results. DCE parameters and treatment response of individual nodes may vary even in a single
patient and so we felt it was important to keep this data for site specific response, however this
could lead to dependency issues in the statistical analysis. Not all patients had a residual mass
in the tumor bed and even when a mass was present it may have been too small or too necrotic
for DCE-MRI analysis. Therefore, although the sample size was sufficient to show significant
differences between SC and SF for primary and nodal sites combined, the sample was not large
Fig 3. Box plots showing pre-treatment AUGC in 33 SCC sites and post-treatment AUGC in SC and SF
residual masses. SC residual masses showed significantly lower AUGC than SF residual masses.
doi:10.1371/journal.pone.0144770.g003
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enough to show a difference when primary and nodal sites were analyzed separately. Small
residual masses in the primary tumor bed were particularly difficult to assess with DCE-MRI
when they formed rims of tissue along the walls of the aerodigestive tract at the interface with
air, as were necrotic nodes, so limiting the role of functional imaging in the post-treatment
neck. Furthermore, contouring a residual abnormality in the post-treatment tumor bed can be
more difficult than contouring the pre-treatment tumor because of the complex treatment
induced signal abnormalities in the adjacent normal structures. Finally, patients with human
papillomavirus (HPV) positive SCCs are more responsive to treatment with better treatment
Fig 4. Receiver-operating characteristics curve. Receiver operating characteristic curve for the %
change in AUGC of a post-treatment residual mass, for distinguishing between SC residual masses
and SF residual masses. Area under the curve of 0.77 when using a > 19.78% increase in AUGC to predict
SF.
doi:10.1371/journal.pone.0144770.g004
Table 4. Diagnostic performance of % change in AUGC to identify residual masses with SF.
Threshold > 19.78
p-value 0.005
True positive 10
False positive 4
True negative 15
False negative 4
Sensitivity 71.4%
Specificity 78.9%
Accuracy 75.8%
Positive predictive value 71.4%
Negative predictive value 78.9%
doi:10.1371/journal.pone.0144770.t004
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outcome, and successfully treated cystic nodal metastases may take longer to resolve [27, 28],
but HPV status of many of the SCCs in this study were unknown and therefore the influence of
HPV on treatment outcome for the oropharyngeal SCCs could not be assessed.
Conclusion
In summary, there is little published data for head and neck SCC regarding the diagnostic abil-
ity of post-treatment DCE-MRI, using a pharmacokinetic model, to distinguish between a
residual mass which is benign and one that still contains SCC. Compared to post-treatment
residual masses with SF, those residual masses with SC showed significantly lower kep and
AUGC and a greater % reduction in AUGC, the % change in AUGC remaining significant on
multivariate analysis. In this respect the use of % change in AUGC is promising, but our results
Table 5. Post-treatment residual mass in 19 primary sites and 14 nodal sites; mean DCE parameters (and% change when compared to pre-treat-
ment) for SC residual masses and SF residual masses, based on aminimum of 2 year clinical follow-up.
Parameter Post-treatment Residual
mass with Site Failure (SF)
Post-treatment Residual mass
with Site Control (SC)
p-value comparing residual masses
with SC & SF using Logistic
regression
Odds
Ratio (OR)
95% CI
for OR
Primary
Tumor Sites
n = 7 n = 12
Ktrans (min-1) 0.40 ± 0.15 0.30 ± 0.18 0.202 53.762 0.118–
999.
% Change
Ktrans
39.80 ± 95.63 -16.42 ± 58.81 0.167 1.011 0.995–
1.028
kep (min
-1) 0.50 ± 0.21 0.41 ± 0.26 0.422 5.324 0.090–
314.83
% Change kep -17.09 ± 59.01 -19.63 ± 61.39 0.926 1.001 0.985–
1.017
ve 0.76 ± 0.16 0.81 ± 0.25 0.635 0.341 0.004–
28.829
% Change ve 63.36 ± 38.52 26.53 ± 52.66 0.132 1.018 0.995–
1.041
AUGC (mMs) 2.96 ± 1.17 2.28 ± 0.77 0.147 2.326 0.744–
7.266
% Change
AUGC
33.18 ± 56.00 -10.12 ± 34.54 0.077 1.025 0.997–
1.053
Nodal Tumor
Sites
n = 7 n = 7
Ktrans (min-1) 0.31 ± 0.11 0.20 ± 0.10 0.136 - -
% Change
Ktrans
-7.62 ± 26.71 -26.98 ± 36.86 0.266 1.021 0.984–
1.060
kep (min
-1) 0.54 ± 0.26 0.23 ± 0.08 0.110 - -
% Change kep -14.71 ± 49.71 -59.37 ± 24.34 0.133 1.050 0.985–
1.118
ve 0.74 ± 0.22 0.85 ± 0.30 0.408 0.150 0.002–
13.428
% Change ve 42.84 ± 57.99 105.05 ± 122.92 0.248 0.992 0.978–
1.006
AUGC (mMs) 3.04 ± 1.03 1.83 ± 1.05 0.078 3.280 0.877–
12.269
% Change
AUGC
52.09 ± 75.90 -16.92 ± 50.90 0.093 1.019 0.997–
1.042
± Standard deviation.
doi:10.1371/journal.pone.0144770.t005
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in the post-treatment are based on a relatively small patient population and further studies are
needed. This study failed to identify any pre-treatment DCE-MRI parameters that were predic-
tive of treatment failure at specific primary or nodal sites in the head and neck and DCE-MRI
analysis using pharmacokinetic models remains a technically challenging technique to perform
in the head and neck.
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